Outcome Without Adjuvant Systemic Treatment in Stage I ER+/HER2− Breast Cancer Patients
abstract
This abstract is available on the publisher's site.
Access this abstract now Full Text Available for ClinicalKey SubscribersBACKGROUND
Adjuvant systemic treatments (AST) reduce mortality, but have associated short- and long-term toxicities. Careful selection of patients likely to benefit from AST is needed. We evaluated outcome of low-risk breast cancer patients of the EORTC 10041/BIG 3-04 MINDACT trial who received no AST.
PATIENTS AND METHODS
Patients with estrogen receptor positive, HER2 negative, lymph node negative tumors ≤2cm who received no AST were matched 1:1 to patients with similar tumor characteristics treated with adjuvant endocrine therapy (ET), using propensity score matching and exact matching on age, genomic risk (70-gene signature) and grade. In a posthoc analysis, distant metastasis-free interval (DMFI) and overall survival (OS) were assessed by Kaplan-Meier analysis and hazard ratios (HR) by Cox regression. Cumulative incidences of locoregional recurrence (LRR) and contralateral breast cancer (CBC) were assessed with competing risk analyses.
RESULTS
At 8 years, DMFI rates were 94.8% (95%CI: 92.7-96.9%) in 509 patients receiving no AST, and 97.3% (95%CI: 95.8-98.8%) in 509 matched patients who received only ET (absolute difference: 2.5%, HR 0.56 (95%CI: 0.30-1.03)). No statistically significant difference was seen in 8-year OS rates, 95.4% (95%CI: 93.5-97.4%) in patients receiving no AST, and 95.6% (95%CI: 93.8-97.5%) in patients receiving only ET (absolute difference: 0.2%, HR 0.86 (95%CI: 0.53-1.41)). Cumulative incidence rates of LRR and CBC were 4.7% (95%CI: 3.0-7.0%) and 4.6% (95%CI: 2.9-6.9%) in patients receiving no AST versus 1.4% (95%CI: 0.6-2.9%) and 1.5% (95%CI: 0.6-3.1%) in patients receiving only ET.
CONCLUSIONS
In patients with stage I low-risk breast cancer, the effect of ET on DMFI was limited, but overall significantly fewer breast cancer events were observed in patients who received ET, after the relatively short follow-up of 8 years. These benefits and side effects of ET should be discussed with all patients, even those at a very low risk of distant metastasis.
Click on any of these tags to subscribe to Topic Alerts. Once subscribed, you can get a single, daily email any time PracticeUpdate publishes content on the topics that interest you.
Visit your Preferences and Settings section to Manage All Topic Alerts
Additional Info
Outcome without any adjuvant systemic treatment in stage I ER+/HER2- breast cancer patients included in the MINDACT trial
Ann. Oncol 2021 Nov 30;[EPub Ahead of Print], JMNL Cardozo, D Byng, CA Drukker, MK Schmidt, MA Binuya, LJV' Veer, F Cardoso, M Piccart, CH Smorenburg, C Poncet, EJT RutgersFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.